• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ISEE

ISEE

IVERIC bio, Inc.

NASDAQHealthcareBiotechnologyUS

USD39.95

+0.15 (+0.38%)

Company Profile

CEO

Glenn P. Sblendorio

IPO Date

2013-09-25

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$39.86

Prev. Close

$39.80

Day Low

$39.85

Day High

$39.98

52W Low

$9.39

52W High

$39.99

Market Cap

$5.51B

Volume

10.80M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

43.4%

Avg Negative

11.1%

Avg Neutral

45.6%

News Feed

Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura® Ahead of Schedule

Business Wire·7/26/2021·↑ positive

Iveric Bio Appoints Christopher Simms as Chief Commercial Officer

Business Wire·7/19/2021·↑ positive

IVERIC bio (ISEE) Enters Overbought Territory

Zacks Investment Research·7/14/2021·↓ negative

Iveric Bio Raises $100M Via Equity To Fund Zimura Development In Geographic Atrophy

Benzinga·7/13/2021·↑ positive

IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock

Business Wire·7/12/2021·↑ positive

IVERIC bio, Inc. Announces Proposed Offering of Common Stock

Business Wire·7/12/2021·↑ positive

Do Options Traders Know Something About IVERIC bio (ISEE) Stock We Don't?

Zacks Investment Research·7/12/2021·↓ negative

IVERIC bio Stock Increased 11.87%: Why It Happened

Pulse2·7/7/2021·↑ positive

ISEE Stock Price Increases Over 30% Pre-Market: Why It Happened

Pulse2·7/6/2021·↑ positive

Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration

Business Wire·7/6/2021·↑ positive